Johnson & Johnson Offers $5.5 Billion to Settle U.S. Talc Baby Powder Lawsuits

What Happened

On Monday, July 27, 2026, Johnson & Johnson (J&J) announced it would pay up to $5.5 billion (approximately £4.14 billion) to settle tens of thousands of U.S. lawsuits alleging its talc‑based baby powder causes ovarian cancer.

The company said the offer covers about 69,000 cases, which it described as "most of the remaining talc‑related claims" in state and federal courts.

J&J stated it would pay up to $3 billion next year, with no further payments due before 2028, and the settlement will only become final if legal firms representing at least 95% of the claimants accept it.

What the Evidence Establishes

The settlement proposal was confirmed by three independent outlets: BBC World, an operative Telegram feed, and Al Jazeera News, all reporting the same $5.5bn figure and the 69,000‑case coverage.

Al Jazeera added that the settlement accounts for 99.75% of outstanding talc‑related cases in the United States.

J&J’s vice president of litigation, Erik Haas, said the allegations are "meritless" but the company wishes to "finally resolve the matter" and "put this matter behind it".

The offer follows a federal court victory earlier in July 2026 that questioned plaintiffs’ ability to prove talc as the direct cause of ovarian cancer.

Where the Accounts Conflict

While BBC and Telegram sources said the deal covers "most of the remaining talc‑related claims," Al Jazeera specified the figure as 99.75% of outstanding U.S. talc cases.

Al Jazeera also noted the World Health Organization’s 2024 classification of talc as "probably carcinogenic to humans," a detail absent from the BBC and Telegram reports.

The UK litigation, involving over 7,000 potential claimants filed in October 2025, is explicitly excluded from the settlement according to Al Jazeera, whereas the other sources did not mention any extraterritorial carve‑out.

Context and Stakes

Lawsuits over J&J’s talc‑based baby powder began as early as 2009, with the first U.S. jury award in 2016 of $72 million (later overturned).

J&J stopped selling talc‑based baby powder in the United States in 2020 and worldwide in 2023, shifting to a cornstarch formula.

The proposed settlement would resolve a liability that has weighed on the New Jersey‑based healthcare giant for years, potentially freeing capital for its pharmaceutical and medical‑device divisions.

Kenvue, the consumer‑health business spun off in 2022, retains liability for talc products outside North America, meaning the settlement does not affect those overseas claims.

What to Watch Next

Plaintiffs’ law firms must secure approval from at least 95% of claimants; if that threshold is not met, the offer lapses and litigation could resume.

A federal judge will need to sign off on the settlement after the plaintiff‑side acceptance, a process that could take several weeks.

Investors will monitor J&J’s stock (ticker: JNJ) for volatility; historically, mass‑tort settlements trigger a 3‑5% short‑term price move depending on perceived adequacy of the payout.

Separately, the UK talc litigation proceeding in London courts may proceed independently, offering a test of whether the U.S. settlement influences foreign jurisdictions.

Bottom Line

Johnson & Johnson’s $5.5bn offer represents one of the largest proposed resolutions in U.S. product‑liability history, aiming to close a multi‑year talc controversy that has generated billions in legal costs and jury awards.

Success hinges on obtaining near‑unanimous plaintiff consent; failure would leave J&J facing continued costly litigation and potentially larger payouts.

If approved, the settlement would allow J&J to allocate resources toward core healthcare businesses while removing a major overhang on its balance sheet.